CARIPUL® Is Now Available Under Exceptional Access Program


Source: Actelion Pharmaceuticals Press Release

CARIPUL® (room temperature stable epoprostenol) Is Now Available Under Exceptional Access Program for Patients with Ontario Drug Benefit Coverage.

CARIPUL®, a recently-introduced room temperature stable formulation of epoprostenol for continuous IV infusion in patients with NYHA functional class III or IV pulmonary hypertension, is now being reimbursed under the Exceptional Access Program of Ontario’s Ministry of Health and Long-term Care.  This EAP coverage was included in the February 1, 2014 edition of the EAP criteria published by the Ministry. In order to receive coverage, a PAH patient must be eligible to receive benefits under the Ontario Drug Benefit (ODB) program and meet the criteria for reimbursement:

  • NYHA functional class III or IV PAH
  • Idiopathic (primary) PAH, familial (heritable) PAH, anorexigen-induced PAH, or PAH secondary to connective tissue disease, congenital heart disease, or HIV

CARIPUL® offers patients an expanded stability profile and the convenience of prolonged refrigerated storage – something not available with other epoprostenol medications currently approved in Canada.

Quebec, New Brunswick and Nova Scotia had also decided in recent months to cover Caripul under their respective provincial plans. Quebec listed Caripul in the  October 2013 RAMQ liste de médicaments,  and New Brunswick  added Caripul to the  February 2014 edition of the New Brunswick Public Drug Program formulary . Nova Scotia Capital Health has also added Caripul to its formulary, effective December 19th, 2013.    Other provinces are reviewing Caripul and are expected to make funding decisions in the coming months. 

Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter